Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
If you want tighter expense control and explicit assignment of funds, zero based budgeting can be worth trying. This intro explains potential gains and a simple starting point.
26,653 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Marvell Technology faces a pivotal 2027 path as AI infrastructure demand compounds. This piece lays out a fresh, data...
Alphabet is shifting from relying on Broadcom to building its own AI chips, aiming to feed GOOG’s hyperscale cloud wh...
NIO delivered a surprising Q4 2025 GAAP profit and outlined a 2026 path to positive non-GAAP earnings, supported by m...
Compass has filed ethics complaints against Zillow across 26 states, highlighting disputes over how active listings a...
American manufacturers are racing to deploy fully automated, lights-out factories in North America as robotics and AI...
A unique tax window opens after the last paycheck and before first RMDs, offering a potential 12% rate for early reti...
As natural gas swings capture traders’ attention, UNG and FCG offer competing paths: near-term futures exposure vs. e...
Tesla faces a pivotal Q2 print as shares struggle in 2026. While deliveries rose, investors will be watching margins,...
Pred secures a $2.5 million funding round led by ACCEL, aiming to deliver the fastest on-chain sports prediction trad...
January data show a pending home sales fall, signaling continued headwinds for buyers even as rates move modestly low...
Bitcoin trades below the $70,000 mark as bear market fears grow and investors watch a potential CLARITY Act vote. Thi...